Evidence map›Paper›PMID 28462377›Full record

ReviewCellular and molecular gastroenterology and hepatology2017

Gastric Cancer in the Era of Precision Medicine.

Xi Liu, Stephen J Meltzer

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular and molecular gastroenterology and hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
19.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. The Human Gastric Juice: A Promising Source for Gastric Cancer Biomarkers.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Xi LiuDepartment of Pathology, First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, Shaanxi, China.
Stephen J MeltzerDivision of Gastroenterology, Department of Medicine, and Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Johns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Translational Research Enhancement CoreP30DK089502 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI ZACHOS, NICHOLAS CONSTANTINE · 2011 to 2020
$12.0M
Facile screening for esophageal cancer in LMICsUH3CA211457 · NCI · JOHNS HOPKINS UNIVERSITY · PI MELTZER, STEPHEN J, WANG, TZA-HUEI JEFF · 2019 to 2021
$2.8M
(PQC-1) Driver Events In IBD-Associated Neoplastic ProgressionR01CA190040 · NCI · JOHNS HOPKINS UNIVERSITY · PI MELTZER, STEPHEN J, SELARU, FLORIN · 2014 to 2017
$2.5M
Facile screening for esophageal cancer in LMICsUG3CA211457 · NCI · JOHNS HOPKINS UNIVERSITY · PI MELTZER, STEPHEN J, WANG, TZA-HUEI JEFF · 2017 to 2018
$861k
NCI NIH HHS R01 CA190040NCI NIH HHS UG3 CA211457NCI NIH HHS UH3 CA211457NIDDK NIH HHS P30 DK089502
6 · The paper itself

Abstract

Gastric cancer (GC) remains the third most common cause of cancer death worldwide, with limited therapeutic strategies available. With the advent of next-generation sequencing and new preclinical model technologies, our understanding of its pathogenesis and molecular alterations continues to be revolutionized. Recently, the genomic landscape of GC has been delineated. Molecular characterization and novel therapeutic targets of each molecular subtype have been identified. At the same time, patient-derived tumor xenografts and organoids now comprise effective tools for genetic evolution studies, biomarker identification, drug screening, and preclinical evaluation of personalized medicine strategies for GC patients. These advances are making it feasible to integrate clinical, genome-based and phenotype-based diagnostic and therapeutic methods and apply them to individual GC patients in the era of precision medicine.

Indexed as

Cancer GenomicsCIMP, CpG island methylator phenotypeCIN, chromosomally unstable/chromosomal instabilityEBV, Epstein-Barr virusGAPPS, gastric adenocarcinoma and proximal polyposis of the stomachGastric CancerGC, gastric cancerGTPase, guanosine triphosphataseHDGC, hereditary diffuse gastric cancerhPSC, human pluripotent stem celllncRNA, long noncoding RNALOH, loss of heterozygositymiRNA, microRNAMolecular ClassificationMSI-H, high microsatellite instabilityMSI, microsatellite unstable/instabilityMSS/EMT, microsatellite stable with epithelial-to-mesenchymal transition featuresNGS, next-generation sequencingPDX, patient-derived tumor xenograftsPreclinical ModelsTCGA, The Cancer Genome AtlasTGF, transforming growth factor

Identifiers

PMID28462377
PMCPMC5404028
OpenAlexW2590096890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.